Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2677 to 2682 of 2682 entries
Sorted by: Best Match Show Resources per page
Genotype-Phenotype Correlation in .

Kidney international reports

Nagano C, Takaoka Y, Kamei K, Hamada R, Ichikawa D, Tanaka K, Aoto Y, Ishiko S, Rossanti R, Sakakibara N, Okada E, Horinouchi T, Yamamura T, Tsuji Y, Noguchi Y, Ishimori S, Nagase H, Ninchoji T, Iijima K, Nozu K.
PMID: 34386660
Kidney Int Rep. 2021 May 19;6(8):2114-2121. doi: 10.1016/j.ekir.2021.05.009. eCollection 2021 Aug.

METHODS: We conducted a systematic review of 174 cases with RESULTS: The median age of developing ESKD was 1.17 years. A comparative study was conducted among three CONCLUSION: Not only the DNA-binding site but also C2H2 zinc finger structure...

Cite
Nagano C, Takaoka Y, Kamei K, et al. Genotype-Phenotype Correlation in . Kidney Int Rep. 2021;6(8):2114-2121doi: 10.1016/j.ekir.2021.05.009.
Nagano, C., Takaoka, Y., Kamei, K., Hamada, R., Ichikawa, D., Tanaka, K., Aoto, Y., Ishiko, S., Rossanti, R., Sakakibara, N., Okada, E., Horinouchi, T., Yamamura, T., Tsuji, Y., Noguchi, Y., Ishimori, S., Nagase, H., Ninchoji, T., Iijima, K., & Nozu, K. (2021). Genotype-Phenotype Correlation in . Kidney international reports, 6(8), 2114-2121. https://doi.org/10.1016/j.ekir.2021.05.009
Nagano, China, et al. "Genotype-Phenotype Correlation in ." Kidney international reports vol. 6,8 (2021): 2114-2121. doi: https://doi.org/10.1016/j.ekir.2021.05.009
Nagano C, Takaoka Y, Kamei K, Hamada R, Ichikawa D, Tanaka K, Aoto Y, Ishiko S, Rossanti R, Sakakibara N, Okada E, Horinouchi T, Yamamura T, Tsuji Y, Noguchi Y, Ishimori S, Nagase H, Ninchoji T, Iijima K, Nozu K. Genotype-Phenotype Correlation in . Kidney Int Rep. 2021 May 19;6(8):2114-2121. doi: 10.1016/j.ekir.2021.05.009. eCollection 2021 Aug. PMID: 34386660; PMCID: PMC8343804.
Copy Download .nbib Format: NLM
Isotopic evidence of plutonium release into the environment from the Fukushima DNPP accident.

Scientific reports

Zheng J, Tagami K, Watanabe Y, Uchida S, Aono T, Ishii N, Yoshida S, Kubota Y, Fuma S, Ihara S.
PMID: 22403743
Sci Rep. 2012;2:304. doi: 10.1038/srep00304. Epub 2012 Mar 08.

The Fukushima Daiichi nuclear power plant (DNPP) accident caused massive releases of radioactivity into the environment. The released highly volatile fission products, such as (129m)Te, (131)I, (134)Cs, (136)Cs and (137)Cs were found to be widely distributed in Fukushima and...

Cite
Zheng J, Tagami K, Watanabe Y, et al. Isotopic evidence of plutonium release into the environment from the Fukushima DNPP accident. Sci Rep. 2012;2:304doi: 10.1038/srep00304.
Zheng, J., Tagami, K., Watanabe, Y., Uchida, S., Aono, T., Ishii, N., Yoshida, S., Kubota, Y., Fuma, S., & Ihara, S. (2012). Isotopic evidence of plutonium release into the environment from the Fukushima DNPP accident. Scientific reports, 2304. https://doi.org/10.1038/srep00304
Zheng, Jian, et al. "Isotopic evidence of plutonium release into the environment from the Fukushima DNPP accident." Scientific reports vol. 2 (2012): 304. doi: https://doi.org/10.1038/srep00304
Zheng J, Tagami K, Watanabe Y, Uchida S, Aono T, Ishii N, Yoshida S, Kubota Y, Fuma S, Ihara S. Isotopic evidence of plutonium release into the environment from the Fukushima DNPP accident. Sci Rep. 2012;2:304. doi: 10.1038/srep00304. Epub 2012 Mar 08. PMID: 22403743; PMCID: PMC3297203.
Copy Download .nbib Format: NLM
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study.

Frontiers in oncology

Jantus-Lewintre E, Massutí Sureda B, González Larriba JL, Rodríguez-Abreu D, Juan O, Blasco A, Dómine M, Provencio Pulla M, Garde J, Álvarez R, Maestu I, Pérez de Carrión R, Artal Á, Rolfo C, de Castro J, Guillot M, Oramas J, de Las Peñas R, Ferrera L, Martínez N, Serra Ò, Rosell R, Camps C.
PMID: 34381717
Front Oncol. 2021 Jul 26;11:695038. doi: 10.3389/fonc.2021.695038. eCollection 2021.

Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated...

Cite
Jantus-Lewintre E, Massutí Sureda B, González Larriba JL, et al. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. Front Oncol. 2021;11:695038doi: 10.3389/fonc.2021.695038.
Jantus-Lewintre, E., Massutí Sureda, B., González Larriba, J. L., Rodríguez-Abreu, D., Juan, O., Blasco, A., Dómine, M., Provencio Pulla, M., Garde, J., Álvarez, R., Maestu, I., Pérez de Carrión, R., Artal, �. �., Rolfo, C., de Castro, J., Guillot, M., Oramas, J., de Las Peñas, R., Ferrera, L., Martínez, N., Serra, �. �., Rosell, R., & Camps, C. (2021). Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. Frontiers in oncology, 11695038. https://doi.org/10.3389/fonc.2021.695038
Jantus-Lewintre, Eloisa, et al. "Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study." Frontiers in oncology vol. 11 (2021): 695038. doi: https://doi.org/10.3389/fonc.2021.695038
Jantus-Lewintre E, Massutí Sureda B, González Larriba JL, Rodríguez-Abreu D, Juan O, Blasco A, Dómine M, Provencio Pulla M, Garde J, Álvarez R, Maestu I, Pérez de Carrión R, Artal Á, Rolfo C, de Castro J, Guillot M, Oramas J, de Las Peñas R, Ferrera L, Martínez N, Serra Ò, Rosell R, Camps C. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. Front Oncol. 2021 Jul 26;11:695038. doi: 10.3389/fonc.2021.695038. eCollection 2021. PMID: 34381717; PMCID: PMC8350788.
Copy Download .nbib Format: NLM
Live European School of Oncology e-Sessions (e-ESO).

Critical reviews in oncology/hematology

Siano M, Marangoni F, Pavlidis N, Peccatori FA, Aapro M, Eniu A, Rolfo C, Cavalli F, Costa A.
PMID: 33741505
Crit Rev Oncol Hematol. 2021 Jul;163:103301. doi: 10.1016/j.critrevonc.2021.103301. Epub 2021 Mar 16.

The European School of Oncology (ESO) embarked on an online educational project, starting with live sessions in 2008 (e-ESO). Our scholars and young oncologists identified the need to be offered independent high-level online education with contributions from experts around...

Cite
Siano M, Marangoni F, Pavlidis N, et al. Live European School of Oncology e-Sessions (e-ESO). Crit Rev Oncol Hematol. 2021;163:103301doi: 10.1016/j.critrevonc.2021.103301.
Siano, M., Marangoni, F., Pavlidis, N., Peccatori, F. A., Aapro, M., Eniu, A., Rolfo, C., Cavalli, F., & Costa, A. (2021). Live European School of Oncology e-Sessions (e-ESO). Critical reviews in oncology/hematology, 163103301. https://doi.org/10.1016/j.critrevonc.2021.103301
Siano, Marco, et al. "Live European School of Oncology e-Sessions (e-ESO)." Critical reviews in oncology/hematology vol. 163 (2021): 103301. doi: https://doi.org/10.1016/j.critrevonc.2021.103301
Siano M, Marangoni F, Pavlidis N, Peccatori FA, Aapro M, Eniu A, Rolfo C, Cavalli F, Costa A. Live European School of Oncology e-Sessions (e-ESO). Crit Rev Oncol Hematol. 2021 Jul;163:103301. doi: 10.1016/j.critrevonc.2021.103301. Epub 2021 Mar 16. PMID: 33741505.
Copy Download .nbib Format: NLM
Heterobivalent Ligand for the Adenosine A.

Journal of medicinal chemistry

Pulido D, Casadó-Anguera V, Gómez-Autet M, Llopart N, Moreno E, Casajuana-Martin N, Ferré S, Pardo L, Casadó V, Royo M.
PMID: 34982555
J Med Chem. 2022 Jan 13;65(1):616-632. doi: 10.1021/acs.jmedchem.1c01763. Epub 2022 Jan 04.

A G protein-coupled receptor heteromer that fulfills the established criteria for its existence

Cite
Pulido D, Casadó-Anguera V, Gómez-Autet M, et al. Heterobivalent Ligand for the Adenosine A. J Med Chem. 2022;65(1):616-632doi: 10.1021/acs.jmedchem.1c01763.
Pulido, D., Casadó-Anguera, V., Gómez-Autet, M., Llopart, N., Moreno, E., Casajuana-Martin, N., Ferré, S., Pardo, L., Casadó, V., & Royo, M. (2022). Heterobivalent Ligand for the Adenosine A. Journal of medicinal chemistry, 65(1), 616-632. https://doi.org/10.1021/acs.jmedchem.1c01763
Pulido, Daniel, et al. "Heterobivalent Ligand for the Adenosine A." Journal of medicinal chemistry vol. 65,1 (2022): 616-632. doi: https://doi.org/10.1021/acs.jmedchem.1c01763
Pulido D, Casadó-Anguera V, Gómez-Autet M, Llopart N, Moreno E, Casajuana-Martin N, Ferré S, Pardo L, Casadó V, Royo M. Heterobivalent Ligand for the Adenosine A. J Med Chem. 2022 Jan 13;65(1):616-632. doi: 10.1021/acs.jmedchem.1c01763. Epub 2022 Jan 04. PMID: 34982555.
Copy Download .nbib Format: NLM
Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Virseda-Berdices A, Rojo D, Martínez I, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Pérez-Latorre L, Micán R, Barbas C, Resino S, Jiménez-Sousa MA.
PMID: 35032770
Biomed Pharmacother. 2022 Jan 12;147:112623. doi: 10.1016/j.biopha.2022.112623. Epub 2022 Jan 12.

BACKGROUND: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs)...

Cite
Virseda-Berdices A, Rojo D, Martínez I, et al. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomed Pharmacother. 2022;147:112623doi: 10.1016/j.biopha.2022.112623.
Virseda-Berdices, A., Rojo, D., Martínez, I., Berenguer, J., González-García, J., Brochado-Kith, O., Fernández-Rodríguez, A., Díez, C., Hontañon, V., Pérez-Latorre, L., Micán, R., Barbas, C., Resino, S., Jiménez-Sousa, M. A. (2022). Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 147112623. https://doi.org/10.1016/j.biopha.2022.112623
Virseda-Berdices, Ana, et al. "Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 147 (2022): 112623. doi: https://doi.org/10.1016/j.biopha.2022.112623
Virseda-Berdices A, Rojo D, Martínez I, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Pérez-Latorre L, Micán R, Barbas C, Resino S, Jiménez-Sousa MA. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomed Pharmacother. 2022 Jan 12;147:112623. doi: 10.1016/j.biopha.2022.112623. Epub 2022 Jan 12. PMID: 35032770.
Copy Download .nbib Format: NLM
Showing 2677 to 2682 of 2682 entries